In vitro activity of tedizolid against gram-positive cocci isolates from patients hospitalized with pneumonia in the United States and Europe, 2014-2016.

In vitro activity of tedizolid against gram-positive cocci isolates from patients hospitalized with pneumonia in the United States and Europe, 2014-2016. by Bensaci M, Tan C, Pfaller MA and Mendes RE published in Journal Infect Diseases and Treatment. 2018; 4 (1): 2

In vitro activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories.

In vitro activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories. by Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL and Castanheira M published in Antimicrob Agents Chemother. 2018; 62 (10): e01230

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016).

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016). by Duncan LR, flamm RK, Sader HS and Mendes RE published in Diagn. Microbiol. Infect. Dis.: in press, 2018.

Trends in Antimicrobial Nonsusceptibility of PCV13-Type Streptococcus pneumoniae Pneumonia in Adults in the United States during 2009-2017.

Trends in Antimicrobial Nonsusceptibility of PCV13-Type Streptococcus pneumoniae Pneumonia in Adults in the United States during 2009-2017. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1444

Comparison of Ceftazidime-Avibactam and Ceftolozane-Tazobactam In Vitro Activities when Tested against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2017)

Comparison of Ceftazidime-Avibactam and Ceftolozane-Tazobactam In Vitro Activities when Tested against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2017). Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA USA
#2427

Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Clinical Trial Anaerobic Isolates.

Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Clinical Trial Anaerobic Isolates. Lead author: D Shortridge, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#2373

Activity of a Long-Acting Echinocandin Rezafungin Tested against Invasive Fungal Isolates Collected Worldwide

Activity of a Long-Acting Echinocandin Rezafungin Tested against Invasive Fungal Isolates Collected Worldwide. Lead author: M Castanheira, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#2400

Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers.

Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers. Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1081

Comparative Activity of Plazomicin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States.

Comparative Activity of Plazomicin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States. Lead author: M Castanheira, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1345

Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials.

Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1364